Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 2) Transcript
Good morning, and welcome to day 2 of our Virtual Alnylam R&D Day event. I'm Christine Lindenboom, Senior Vice President of investor relations and Corporate Communications at Alnylam. With me today are Dr. Arun Sanyal, Virginia Commonwealth University School of Medicine; and Josh Friedman, Senior Director of Clinical Research at Alnylam, who will discuss succeeding in NASH with genetically validated targets. Pushkal Garg, Chief Medical Officer at Alnylam, will cover progress from our earlier-stage clinical pipeline. Kevin Fitzgerald, Chief Scientific Officer at Alnylam, will discuss opportunities beyond the liver with RNAi therapeutics and we will close with an update on our path to a self-sustainable financial profile with Alnylam's CFO, Jeff Poulton.
Before I hand it over to Josh Freeman, I'd like to start with a few brief comments. Today's event is expected to run until approximately noon eastern standard time. Akshay will moderate a Q&A session at the conclusion of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
